Top Companies in Autoinjectors Market

The global autoinjectors market is projected to reach USD 300.46 billion by 2031 from USD 127.30 billion in 2026, at a CAGR of 18.7% during the forecast period.

The autoinjectors market is expanding quickly due to the rising global burden of chronic and autoimmune diseases such as diabetes, multiple sclerosis, and rheumatoid arthritis. Increasing regulatory approvals for autoinjectors, including the use of GLP-1 drugs, have decreased injection frequency and enhanced treatment adherence. The high demand for biosimilars and biologics worldwide is contributing to increased demand. Additionally, greater adoption of self-administered medicines, government support, and favorable reimbursement policies are further driving market growth.

To know about the assumptions considered for the study download the pdf brochure

• In March 2026, Novo Nordisk announced an agreement with telehealth company Hims & Hers Health to expand its access to FDA-approved semaglutide medicines in the US at the same affordable price as other telehealth platforms. This agreement focuses on increasing access to affordable, branded FDA-approved medicines.
• AbbVie invested USD 380 million in North Chicago to expand API manufacturing facilities in the US. These facilities will integrate advanced manufacturing technologies with artificial intelligence; construction will begin in spring 2026 and operations are expected in 2029.

Prominent players in the autoinjectors devices market include Becton, Dickinson and Company (US), SHL Medical (Switzerland), and Ypsomed (Switzerland). However, prominent players in the autoinjectors finished formulation market include Novo Nordisk (Denmark), Eli Lilly and Company (USA), and AbbVie (USA).

AbbVie (US)

AbbVie (US) is a global biopharmaceutical company focused on R&D, manufacturing, marketing, and selling innovative medicines and therapies. The company’s portfolio includes immunology, oncology, aesthetics, neuroscience, eye care products, and other key medicines. AbbVie develops and manufactures products across Africa, Asia Pacific, Europe, Latin America, North America, South America, and the Middle East in more than 70 countries. Its main subsidiaries are AbbVie Biopharmaceuticals LLC (Delaware), AbbVie Products LLC (Georgia), AbbVie S.A. (Argentina), and AbbVie Corporation (Canada).

NOVO NORDISK (DENMARK)

Novo Nordisk is a leading healthcare company primarily focused on manufacturing pharmaceutical products and devices worldwide for a wide range of acute and chronic diseases. The company offers a broad portfolio of essential healthcare products, including pens and needles, smart pens, devices and apps, and certain medicines. It has a global presence in countries such as Belgium, Brazil, China, Denmark, France, Italy, and the US. Additionally, the company operates various R&D centers across Asia Pacific, Europe, and North America. Its main subsidiaries include Novo Nordisk (US), Novo Nordisk Pharmaceutical Industries LP (US), and Novo Nordisk Pharma GmbH (Germany).

ELI LILLY AND COMPANY (US)

Eli Lilly and Company is a major global pharmaceutical company that develops and distributes products for areas such as Cardiometabolic Health, Oncology, Immunology, and Neuroscience. The company markets its products in over 95 countries across the US, Europe, and Asia. Its subsidiaries include Eli Lilly Canada Inc. (Canada), Lilly Deutschland GmbH (Germany), Eli Lilly & Co Pvt. Ltd (India), Eli Lilly Cork Limited (Ireland), and Eli Lilly (Suisse) SA (Geneva).

Market Ranking

The autoinjectors market is consolidated and led by major players, including Becton, Dickinson and Company (US), SHL Medical (Switzerland), and Ypsomed (Switzerland) in autoinjector devices, and Novo Nordisk (Denmark), Eli Lilly and Company (USA), and AbbVie (USA) in finished autoinjector formulations, holding the largest market shares. These leading companies have strong global networks and well-established distribution channels in regions like North America and Europe. They leverage partnerships, advanced R&D, and brand recognition to sustain their dominance. Meanwhile, smaller competitors focus on offering low-cost products and innovative technologies, creating a market landscape that combines dominant global corporations with agile, regional providers.

Related Reports:

Autoinjectors Market by Type (Devices, Finished Formulation), Usage (Disposable, Reusable), Actuation Mechanism (Mechanical, Electronic), Therapy (Rheumatoid Arthritis, Obesity, Diabetes), ROA (SC, IM), Volume (< 3ml, > 3ml) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]